RO7795081 is named as a drug or biological intervention in 3 clinical trials in our USA and China trial registers, 1 of which is recruiting. The lead sponsor is Hoffmann-La Roche. Registered phases: Phase 1 and Phase 2. Conditions studied include Type 2 Diabetes Mellitus; Renal Impairment; Healthy Volunteers.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07741604 | A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions (ClinicalTrials.gov ↗) Renal Impairment |
Phase 1 | Recruiting |
| NCT07112872 | A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes (ClinicalTrials.gov ↗) Type 2 Diabetes Mellitus |
Phase 2 | Active, closed |
| NCT07499050 | A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight (ClinicalTrials.gov ↗) Healthy Volunteers, Overweight or Obesity |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Type 2 Diabetes Mellitus | 1 |
| Renal Impairment | 1 |
| Healthy Volunteers | 1 |
| Overweight or Obesity | 1 |
| Lead sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 3 |
| Register | RO7795081 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RO7795081 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RO7795081 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.